EdiGene (GuangZhou) Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2018-03-05
- Employees
- -
- Market Cap
- -
- Website
- http://www.edigene.com
A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia.
Not Applicable
Active, not recruiting
- Conditions
- Transfusion Dependent Beta-Thalassaemia
- Interventions
- Biological: ET-01
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- EdiGene (GuangZhou) Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05752123
- Locations
- 🇨🇳
PLA 923 Hospital, Nanning, Guangxi, China
A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
Not Applicable
Active, not recruiting
- Conditions
- Relapsed or Refractory B-cell Malignancy(NHL/ALL)
- Interventions
- Biological: ET-02
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- EdiGene (GuangZhou) Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04933825
- Locations
- 🇨🇳
•The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
A Safety and Efficacy Study Evaluating ET-01 in Subjects With Transfusion Dependent β-Thalassaemia
Phase 1
Active, not recruiting
- Conditions
- Transfusion Dependent Beta-Thalassaemia
- Interventions
- Biological: ET-01
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- EdiGene (GuangZhou) Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04925206
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath